The tumor growth data suggest that even though OX40+4-1BB or PD-L1 confers some degree of anti-tumor protection, the additional agents in the hexatherapy regimen provided a substantial contribution to the enhanced therapeutic benefit in the MC38-CEA tumor-bearing mice. The gene discussed is CD274; the disease is neoplasm.